Bavarian Nordic (OTCMKTS:BVNRY – Get Free Report) gapped up before the market opened on Tuesday. The stock had previously closed at $10.8350, but opened at $11.37. Bavarian Nordic shares last traded at $11.37, with a volume of 467 shares traded.
Bavarian Nordic Trading Up 2.6%
The business has a 50 day moving average price of $10.35 and a 200-day moving average price of $9.90. The firm has a market capitalization of $2.70 billion, a PE ratio of 11.48 and a beta of 1.25.
Bavarian Nordic (OTCMKTS:BVNRY – Get Free Report) last posted its quarterly earnings results on Friday, August 21st. The company reported $0.46 earnings per share for the quarter. Bavarian Nordic had a return on equity of 11.97% and a net margin of 24.36%.The firm had revenue of $316.47 million for the quarter.
Bavarian Nordic Company Profile
Bavarian Nordic A/S is a Denmark-based biotechnology company focused on developing, manufacturing and commercializing vaccines. The company serves government agencies, healthcare providers, travelers and other customers through a portfolio of products addressing infectious diseases and public-health preparedness.
Its best-known vaccine is MVA-BN, marketed as Jynneos in the United States and Imvanex in the European Union, for protection against smallpox and mpox. Bavarian Nordic also markets vaccines for rabies, including Rabipur and RabAvert, and for tick-borne encephalitis under the Encepur brand.
See Also
- Five stocks we like better than Bavarian Nordic
- Why onsemi’s Synaptics Pivot Could Be a Game Changer
- AI Chip Demand Gives Linde a New Growth Catalyst
- Qualcomm’s Huawei Deal Adds Strategic Depth to Its AI Expansion
- 3 Sectors Where Volatility Is Creating Entry Points, Not Exit Signals
Receive News & Ratings for Bavarian Nordic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bavarian Nordic and related companies with MarketBeat.com's FREE daily email newsletter.
